Stable Isotope Labeled Tocilizumab Biosimilar – Anti-IL-6R mAb – Research Grade

Reference: PX-TA1030-SIL-1MG


Product type


Expression system


Description of Tocilizumab Biosimilar - Anti-IL-6R mAb - Research Grade

General information on Tocilizumab Therapeutic Antibody

The tocilizumab antibody is an IgG1 kappa monoclonal protein obtained from mouse hybridoma and subsequently humanized for use in antibody therapy. Tocilizumab acts as an immunosuppressant and it has been designed to bind the human interleukin 6 receptor (IL-6R), which occurs in membrane-bound or soluble form. The receptor is known to bind IL-6, a 21-26 kDa glycoprotein, and mediate proinflammatory reactions in response to infections or tissue injuries._x000D_
IL-6 production is triggered locally and only during the early stages of inflammation. Despite its key role in the immune response, IL-6 overproduction has been observed in different chronic inflammatory diseases and some forms of cancer. Moreover, its presence has been linked with the excessive and potentially fatal inflammatory responses known as “cytokine storm.”_x000D_
Tocilizumab is one of the first humanized monoclonal antibodies ever to be licensed and commercialized as an efficient IL6R blocker. Due to its specificity, it is recurrently used to treat autoimmune conditions such as rheumatoid arthritis, cytokine release syndrome (or “cytokine storm”), and polyarticular juvenile idiopathic arthritis; some forms of cancer such as Castleman’s disease; and inflammatory diseases such as giant cell arteritis._x000D_
Recent studies showed that IL-6 levels in COVID-19 patients on ventilators can be 10 times higher in comparison to patients with milder symptoms of the disease. Exacerbated levels of the proinflammatory molecule have previously been observed in other coronavirus-mediated diseases such as the Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). In these diseases as in the case of COVID-19, the leading cause of death appears to be severe lung inflammation in the form of “cytokine storm.”_x000D_
The efficiency of Tocilizumab in the COVID-19 disease has been recently reported in several observational studies, including a study from Italy where researchers reported improved oxygenation in 74% and 65% of the patients on mechanical or non-invasive ventilation, respectively. Multiple randomized, double-blind, and placebo-controlled clinical trials are currently underway to validate the efficiency of this IgG1 antibody for the treatment of the COVID-19 disease. This product is for research use only.

Product nameStable Isotope Labeled Tocilizumab Biosimilar - Anti-IL-6R mAb - Research Grade
SourceCAS 375823-41-9
Expression systemMammalian cells
Molecular weight144.9kDa
BufferPBS pH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage condition4°C for short term; -20°C for long term
Aliases /SynonymsTocilizumab
Related ProductsPX-P4046
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody
SourceCAS 375823-41-9
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2
Isotopic Enrichment99%
Stability1 year


There are no reviews yet.

Be the first to review “Stable Isotope Labeled Tocilizumab Biosimilar – Anti-IL-6R mAb – Research Grade”

Your email address will not be published.



Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us